Silence Therapeutics PLC Sample Contracts
SILENCE THERAPEUTICS PLC AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement September 4, 2020Deposit Agreement • March 9th, 2021 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of September 4, 2020 among SILENCE THERAPEUTICS PLC, a company incorporated under the laws of England and Wales (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
Standard Contracts
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 15th, 2021 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
LICENSE AND COLLABORATION AGREEMENT* by and between SILENCE THERAPEUTICS PLC and MALLINCKRODT PHARMA IP TRADING DAC Dated as of July 18, 2019License and Collaboration Agreement • August 20th, 2020 • Silence Therapeutics PLC • Pharmaceutical preparations
THIS LICENSE AND COLLABORATION AGREEMENT is made and entered into effective as of July 18, 2019 (the “Effective Date”) by and between
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 6th, 2024 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 2, 2024 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT* by and betweenResearch Collaboration, Option and License Agreement • August 20th, 2020 • Silence Therapeutics PLC • Pharmaceutical preparations
THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is made and entered into effective as of March 24, 2020 (the “Effective Date”) by and between
THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE. EXCLUSIVE RESEARCH COLLABORATION, OPTION AND LICENSE...Exclusive Research Collaboration, Option and License Agreement • March 15th, 2023 • Silence Therapeutics PLC • Pharmaceutical preparations
THIS EXCLUSIVE RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT is made and entered into effective as of October 14, 2021 (the “Effective Date”) by and between
Registration Rights AgreementRegistration Rights Agreement • February 8th, 2021 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 4, 2021 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of February 4, 2021 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
SILENCE THERAPEUTICS PLC AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • August 16th, 2022 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 6th, 2024 • Silence Therapeutics PLC • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 2, 2024 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of February 2, 2024 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
